Compare ProShares Ultra Bloomberg Natural Gas ETF (BOIL) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Bloomberg Natural Gas ETF vs McKesson Corporation — how do they compare? ProShares Ultra Bloomberg Natural Gas ETF trades at $21.91, while McKesson Corporation trades at $804.93 (market cap $94.06B). The key difference: McKesson Corporation pays a 0.41% dividend while ProShares Ultra Bloomberg Natural Gas ETF pays none, and McKesson Corporation is trading nearer its 52-week high, ProShares Ultra Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| BOIL | MCK | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $98.62 | $995.69 |
52-Week Low | $21.86 | $659.01 |
Market Cap | — | $94.06B |
Enterprise Value | — | $98.70B |
Dividend Yield | — | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOIL trades at $21.86, down 3.62% on the day, with technical indicators showing a bearish trend despite oversold RSI readings. The stock recently underwent a 1:2 split on May 28, 2026. Natural gas market volatility dominates sentiment, with futures fluctuating based on weather forecasts and LNG demand. Fundamental data remains unavailable, highlighting the speculative nature of this leveraged ETF.
The outlook remains highly speculative given BOIL's leveraged structure and dependence on natural gas price movements. Key risks include contango erosion and weather-driven volatility. Investment opportunity exists for tactical traders betting on natural gas price surges, but long-term value erosion remains a significant concern for buy-and-hold investors.
McKesson (MCK) trades at $812.28, up 0.78% with a bullish technical signal. The stock shows consistent earnings beats, with Q1 2026 EPS of $11.69 exceeding expectations. Revenue grew to $359.05B in 2025, though net margins remain thin at 1.18%. Analysts maintain strong buy consensus (80%) with a $932.83 price target. Recent news highlights growth in specialty pharma and oncology services, supporting positive momentum.
Outlook remains positive driven by earnings strength and sector tailwinds, but risks include policy changes and high liabilities. The stock offers value with a P/E of 21.16 and P/S of 0.25, though investors should monitor debt levels and execution risks amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra Bloomberg Natural Gas ETF
BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.
Read more on BOIL →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
